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experienced relapse when the therapy was stepped down were placed on the previous regimen, with remission for the remaining time.
Outcomes assessed in the review
The outcomes used to derive input parameters for the model were:
for maintenance therapy, the monthly transition probabilities of symptomatic relapse during standard-dose H2RA, lowdose PPI and standard-dose PPI; and for active therapy, the monthly transition probabilities of treatment success with standard-dose PPI and high-dose PPI.
Study designs and other criteria for inclusion in the review
Clinical trials that involved symptom-free patients with healed oesophagitis were selected. For assessing monthly probabilities of treatment success with standard-dose PPI and high-dose PPI, clinical trials involving patient with Savary-Miller classification grade I-III oesophagitis were used.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies Not specified.
Methods used to judge relevance and validity, and for extracting data
Not reported. However, the authors appear to have selected studies appropriate to their study question, and selected information that would assist in their analysis.
Number of primary studies included
Approximately 20 studies were used to derive data for the model.
Methods of combining primary studies
Investigation of differences between primary studies
Not investigated.
Results of the review
For maintenance therapy, the monthly transition probability of symptomatic relapse was: 0.053 (95% confidence interval, CI: 0.051 -0.55) with standard-dose H2RA; 0.026 (95% CI: 0.024 -0.031) with low-dose PPI; and 0.021 (95% CI: 0.018 -0.023) with standard-dose PPI.
For active therapy, the monthly transition probability of response was: 
Measure of benefits used in the economic analysis
The measures of benefit used were the number of symptom-free patient-years gained and the number of QALYs gained. The symptom-free patients-years gained were calculated from the model. Utility scores for symptomatic GERD were derived from a published study using the time trade-off method and were used to estimate the QALYs. The utility score for the symptom-free states of GERD was assumed to be unity. The health states were not valued in this study.
Direct costs
The costs were estimated from the perspective of a public health organisation. The quantities were estimated using actual data and they were retrieved retrospectively from the medical records of GERD patients treated in a public hospital in Hong Kong. The cost analysis focused on the cost of clinic visits, hospitalisation, drugs for the management of GERD, and diagnostic tests. The quantities and the costs were not reported separately. Charges were used to proxy prices for itemised health care services in public hospitals. These were retrieved from a published source (Hong Kong Gazette). The drug costs were based on the Hospital Authority-specific acquisition costs. The time horizon of the model was varied from 1 to 5 years in the sensitivity analysis. Discounting was not carried out but, as the time-horizon of the base-case model was only one year, it would not have been relevant. The dates to which the costs related and the price year were not reported.
Statistical analysis of costs
There was no stochastic analysis of the costs.
Indirect Costs
No indirect costs were reported.
Currency

US dollars ($). No conversion rate was reported.
Sensitivity analysis
A sensitivity analysis, with all the clinical probabilities and direct medical costs, was carried out to examine the robustness of the data. The ranges for the monthly transition probabilities and monthly direct medical costs of symptomatic and asymptomatic months were based on the 95% CIs. The ranges used for the other monthly costs were +/-20% of the base-case value. The effect of generic pricing of omeprazole was also examined.
